Dr Hamilton talks to ecancer about results from VERITAC-2, the first global phase 3 clinical trial of a PROTAC, a targeted therapy that breaks down the oestrogen receptors found on cancer cells.

The study showed that the PROTAC vepdegestrant could extend progression-free survival for people with previously treated oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer with an ESR1 mutation.

For further information read the news story here